Skip to main content
. 2020 Aug 22;105(12):e4593–e4604. doi: 10.1210/clinem/dgaa577

Table 2.

Potential Prognostic Factors and Effect Modifiers Included in Each of the IPD MR Analyses

Outcomes Analyzed Potential Prognostic Factors and Effect Modifiers Included in Each Model
BL HbA1c (PF and EM) BL body weight (PF and EM) T2D duration (PF and EM) eGFR (EM) Hypothyroidism (PF and EM) Heart failure (PF) Smoking status (PF and EM) Age (PF and EM) Sex (PF and EM) Race (PF)
HbA1c change from BL X X X X X X X* X
Body weight change from BL X X X X X X* X X X
HbA1c responders X X X X X X* X
Weight-loss responders X X X X X X* X X X
Composite responders X X X X X X X X X X
Other clinically relevant efficacy outcomes X X X X X* X

Published literature was available for BL HbA1c, BMI, T2D duration, and eGFR (19), hypothyroidism (20), heart failure (21-24), and smoking status (25-27). The baseline value for each outcome was used as a covariate. Composite responder analyses were HbA1c reduction of ≥1.0% and weight-loss of ≥5%, HbA1c <7.0% and weight-loss of ≥5%, and HbA1c <7.0% with no severe or blood glucose–confirmed hypoglycemia and no weight gain. Other clinically relevant efficacy outcomes were change in BMI, waist circumference, diastolic blood pressure, systolic blood pressure, lipid parameters (total cholesterol, triglycerides, LDL-C, HDL-C) and eGFR.

Abbreviations: BL, baseline; BMI, body mass index; eGFR, estimated glomerular filtration rate; EM, potential effect modifier; HDL-C, high-density lipoprotein cholesterol; IPD MR, individual patient data meta-regression; LDL-C, low-density lipoprotein cholesterol; PF, prognostic factor; T2D, type 2 diabetes.

*PF only; EM only.